Compare DAC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | VRDN |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2006 | 2014 |
| Metric | DAC | VRDN |
|---|---|---|
| Price | $161.74 | $21.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $112.50 | $35.46 |
| AVG Volume (30 Days) | 101.2K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | N/A | $279.00 |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $83.56 | $13.18 |
| 52 Week High | $163.64 | $34.29 |
| Indicator | DAC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 46.44 |
| Support Level | $121.29 | $21.40 |
| Resistance Level | N/A | $23.84 |
| Average True Range (ATR) | 2.89 | 0.88 |
| MACD | 0.27 | -0.24 |
| Stochastic Oscillator | 87.94 | 28.87 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.